DDInter630 DDInter1376
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Elotuzumab may lead to a major life threatening interaction when taken with Fingolimod
Elotuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam